- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.11.24 | On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves analysts stunned | ||
| 11.11.24 | FDA approves new CAR-T competitor to Gilead's Tecartus | ||
| 11.11.24 | FDA lifts pause on Novavax flu vaccine trials | ||
| 11.11.24 | AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies | ||
| 11.11.24 | Cigna confirms it is not pursuing Humana acquisition | ||
| 11.11.24 | Thinking inside the box: How SmartLabs is driving new collaborations to support the life science industry in global innovation hubs | ||
| 11.11.24 | Fueling accelerated drug development in autoimmune diseases with a modality-agnostic approach | ||
| 11.11.24 | 7 steps to selecting the right global central lab | ||
| 08.11.24 | Kalaris to go public via reverse merger with AlloVir | ||
| 08.11.24 | Athira exploring strategic alternatives after Alzheimer's failure | ||
| 08.11.24 | Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value | ||
| 08.11.24 | What RFK Jr.'s influence on Trump could mean for pharma | ||
| 07.11.24 | Moderna earnings beat forecasts, but analysts question whether sales spike will last | ||
| 07.11.24 | Sarepta scraps a Duchenne drug as gene therapy sales rise | ||
| 07.11.24 | With Trump victorious, biotech industry's focus turns to his plans for FDA, FTC | ||
| 06.11.24 | Novo sees Wegovy sales rise as supply constraints ease | ||
| 06.11.24 | Acadia sells speedy drug review voucher for $150M | ||
| 06.11.24 | Moderna said to shuffle sales leadership; Vertex records first Casgevy sale | ||
| 06.11.24 | An RNAi renaissance is creating a new generation of startups | ||
| 05.11.24 | Cancer cell therapy from Arcellx, Gilead shows promise in early data | ||
| 05.11.24 | Two former Alexion leaders fight through a tough market to sustain a rare disease biotech | ||
| 05.11.24 | Sana to lay off staff, deepen autoimmune focus in latest retrenchment | ||
| 05.11.24 | Sickle cell patient dies in Beam study of base editing therapy | ||
| 04.11.24 | Neurogene secures $200M ahead of anticipated study readout | ||
| 04.11.24 | Viking data provide latest test of oral obesity drug potential |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
